Schizophrenia asset available for in-licensing
505(b)(2) product for the treatment of schizophrenia available for in-licensing. Multiple markets available including the US. NDA filed in the US in 2019. Approval expected in 2021.
Oral dissolving film makes this product beneficial for patients who resist swallowing. All studies have been completed and a complete response letter issued by the FDA. Manufactured in FDA approved facility.
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2021-10-26 15:52:272021-10-31 18:41:20505(b)(2) formulation for chemotherapy available in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2021-10-26 15:47:292021-10-31 18:41:41505(b)(2) formulation for schizophrenia available in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2021-08-17 15:44:022021-10-31 18:42:01Approved 505(b)(2) available for in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2020-10-10 15:36:022021-10-31 18:07:59Chemotherapy induced nausea and vomiting product available for in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2020-09-20 15:05:132021-10-31 18:08:31Schizophrenia asset available for in-licensing